Press release
Febrile Neutropenia Treatment Market Expected to Grow Notably, Driven by Introduction of Innovative Therapies | DelveInsight
Febrile Neutropenia Market Insights - DelveInsight
DelveInsight's report titled "Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast - 2032 [https://www.delveinsight.com/report-store/febrile-neutropenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", combines comprehensive febrile neutropenia epidemiological data with market trends, an examination of the competitive landscape, and assessments of the patient journey. This report provides valuable insights into the rapidly growing febrile neutropenia market. It is anticipated that the market will expand significantly during the forecast period from 2023 to 2032, driven by an increasing patient population and the introduction of innovative treatment options by leading pharmaceutical and biotechnology companies, including Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, Bristol-Myers Squibb, among others.
Furthermore, the US currently represents the largest market, with the EU4, the UK, and Japan contributing significantly to the overall patient population and market opportunity.
Download the Febrile Neutropenia Market report to understand which factors are driving the Febrile Neutropenia therapeutic market @ Febrile Neutropenia Market Trends [https://www.delveinsight.com/sample-request/febrile-neutropenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Febrile neutropenia is a critical and potentially life-threatening complication, most commonly arising as a severe side effect of cancer therapies such as chemotherapy and radiation. Characterized by fever and a markedly reduced neutrophil count, this condition leaves patients highly vulnerable to infections that can escalate rapidly.
Epidemiologically, the febrile neutropenia burden is substantial and growing. DelveInsight's analysis provides a comprehensive overview of febrile neutropenia patient pools across the 7MM, with segmentation by country and key demographic factors. Notably, approximately 50% of patients with febrile neutropenia develop an infection, and up to 20% of those with severe neutropenia may develop bacteremia. The risk is higher in patients with blood cancers and in those on strong chemotherapy regimens. Older age, poor overall health, and other medical conditions can also increase the risk.
Discover evolving trends in the Febrile Neutropenia patient pool forecasts @ Febrile Neutropenia Epidemiology Analysis [https://www.delveinsight.com/sample-request/febrile-neutropenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Febrile neutropenia management strategies currently involve rapid initiation of broad-spectrum antibiotics, supportive care measures like hydration and fever control, and, in severe cases, the administration of granulocyte colony-stimulating factors (G-CSF) to stimulate neutrophil production. Despite these established approaches, the market continues to face unmet needs, including the demand for more effective therapies that can reduce infection-related morbidity and mortality, minimize treatment interruptions, and improve overall patient outcomes.
Leading therapies include NEULASTA (pegfilgrastim) and NEUPOGEN (filgrastim), both developed and marketed by Amgen. Neulasta is a long-acting option given as a single injection per chemotherapy cycle, while Neupogen is a daily injectable. The introduction of biosimilars and innovative delivery devices, such as the Neulasta Onpro on-body injector, has helped make these treatments more accessible and convenient for patients, supporting faster recovery and reducing complications from febrile neutropenia
Several promising therapies are currently in the febrile neutropenia therapeutic pipeline, focusing on novel mechanisms and improved patient outcomes. Notably, BeyondSpring Pharmaceuticals is developing plinabulin, which has shown positive results in the DUBLIN-3 Phase 3 trial for chemotherapy-induced neutropenia. In this study, plinabulin combined with docetaxel demonstrated a statistically significant improvement in overall survival for patients with non-small cell lung cancer compared with docetaxel alone. Other companies active in this space include Tianjin SinoBiotech Ltd., Evive Biotech, and Enzychem Lifesciences, each working on innovative candidates at various stages of clinical development. These emerging therapies represent new approaches beyond traditional G-CSF agents, with the potential to further reduce infection risk and improve quality of life for patients undergoing chemotherapy.
Recently, there have been important developments in febrile neutropenia treatment. Notably, new clinical research published in March 2025 evaluated the safety and effectiveness of early antibiotic de-escalation in patients with febrile neutropenia, offering new insights for antimicrobial stewardship and patient care. Additionally, the ASCO 2025 conference featured updated clinical data on efbemalenograstim alfa (RYZNEUTA) for the prevention of febrile neutropenia in patients receiving intermediate-risk chemotherapy regimens, highlighting ongoing advancements in supportive care for cancer patients.
Discover recent advancements in the Febrile Neutropenia treatment landscape @ Febrile Neutropenia Recent Developments [https://www.delveinsight.com/sample-request/febrile-neutropenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Looking ahead, the febrile neutropenia market is expected to benefit from continued innovation, a growing patient pool, and heightened awareness of the condition's clinical impact. As companies advance novel therapeutics and address longstanding unmet needs, the market is set for transformation, offering improved outcomes for patients at risk of this serious complication. For industry participants and healthcare providers, staying abreast of these developments is essential for optimizing treatment strategies and capitalizing on emerging opportunities in the febrile neutropenia market.
Table of Contents
1. Key Insights
2. Executive Summary of Febrile Neutropenia
3. Competitive Intelligence Analysis for Febrile Neutropenia
4. Febrile Neutropenia: Market Overview at a Glance
5. Febrile Neutropenia: Disease Background and Overview
6. Patient Journey
7. Febrile Neutropenia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Febrile Neutropenia Unmet Needs
10. Key Endpoints of Febrile Neutropenia Treatment
11. Febrile Neutropenia Marketed Products
12. Febrile Neutropenia Emerging Therapies
13. Febrile Neutropenia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Febrile Neutropenia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports:
Febrile Neutropenia Pipeline Insight [https://www.delveinsight.com/sample-request/febrile-neutropenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Febrile Neutropenia Pipeline Insight provides comprehensive insights about the Febrile Neutropenia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Febrile Neutropenia companies, including Daewoong Pharmaceutical, RedHill Biopharma, Allakos, Hanmi Pharmaceutical, Trio Medicines, and Bristol-Myers Squibb, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=febrile-neutropenia-treatment-market-expected-to-grow-notably-driven-by-introduction-of-innovative-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Febrile Neutropenia Treatment Market Expected to Grow Notably, Driven by Introduction of Innovative Therapies | DelveInsight here
News-ID: 4062441 • Views: …
More Releases from ABNewswire
The Journey of Scoopearth to Scoopearth.in - A Startup Media Revolution
In a bold and strategic move, Scoopearth [https://scoopearth.in/], one of India's most trusted startup media platforms, has officially transitioned from Scoopearth.com to Scoopearth.in. This evolution marks a new chapter in the company's journey toward becoming a leading hub for startup stories, business insights, entrepreneurial news and Podcast.
Founded by Niraj Kumar, Deepika Khare and Anamika Sinha, Scoopearth has been at the forefront of startup journalism, delivering high-value content that inspires, educates,…
Hepatitis A Market Outlook: Strong Pipeline, Strategic Collaborations, and Incre …
The Hepatitis A market is projected to experience robust growth, fueled by the launch of innovative therapies, rising disease prevalence, and heightened healthcare investments across key regions. Industry leaders, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, Sinovac Biotech Co., Ltd, Sanofi, GlaxoSmithKline, Crucell Holland BV, and Merck, among others, are at the forefront of research and development initiatives in this therapeutic area.
DelveInsight's latest report titled "Hepatitis A…
Phenylketonuria Market Growth Accelerates With SEPHIENCE FDA Approval and Promis …
DelveInsight's comprehensive Phenylketonuria Market Insight, Epidemiology and Market Forecast - 2034 report provides crucial intelligence for pharmaceutical companies, investors, and healthcare stakeholders navigating the evolving Phenylketonuria therapeutic landscape.
Key Takeaways and Recent Developments
*
Phase 3 APHENITY Trial Data Reveal Robust Diet Liberalization: In March 2025, PTC Therapeutics presented new APHENITY results showing that 97% of participants in the open-label extension were able to liberalize their diet while on sepiapterin treatment, with…
Myasthenia Gravis Landscape: Regeneron's NIMBLE Trial Success with Cemdisiran, F …
DelveInsight's latest analysis highlights the transformative potential of Regeneron Pharmaceuticals' positive Phase 3 NIMBLE trial results for cemdisiran in generalized myasthenia gravis (gMG). This landmark achievement marks a significant advancement in complement inhibition therapy, offering new hope for patients suffering from this chronic autoimmune neuromuscular disorder characterized by muscle weakness and rapid fatigue due to disrupted communication at the neuromuscular junction.
DelveInsight Business Research's latest analysis highlights the transformative potential of…
More Releases for Febrile
Febrile Seizures Market Business Growth and Industry Development by 2034
The Febrile Seizures Market Is Set To Grow At An Estimated CAGR Of 6.2% From 2025 To 2034, Rising From $3.2 Billion In 2024 To $5.6 Billion By 2034.
On April 10, 2025, Exactitude Consultancy., Ltd. released a research report titled "Febrile Seizures Market" This report offers a new perspective on the Febrile Seizures Market covering an extensive range of aspects including market overview, expenditure analysis, import trends, segmentation, key players,…
Febrile Seizures Market: Global Industry Analysis and Forecast (2024-2030)
Febrile Seizures Market to reach USD 1573.16 Mn at a CAGR of 4.5 percent over the forecast period
The Febrile Seizures Market was valued at USD 1156 Million in 2023, with revenue expected to grow at a CAGR of 4.5%, reaching nearly USD 1573.16 Million by 2030.
To access more details regarding this research, visit the following webpage:https://www.stellarmr.com/report/Febrile-Seizures-Market/2064
Febrile Seizures Market Scope and Research Methodology
The Febrile Seizures Market report employs an extensive research…
Febrile Seizures Market Anticipates Growth in Forecast Period 2024-2031
The "Febrile Seizures Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Acute Febrile Neutrophilic Dermatosis Market - Defending Skin Integrity with Adv …
Newark, New Castle, USA - new report, titled Acute Febrile Neutrophilic Dermatosis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Acute Febrile Neutrophilic Dermatosis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Acute Febrile Neutrophilic Dermatosis market. The report offers…
Acute Febrile Neutrophilic Dermatosis Market Insights, Forecast to 2031
Acute Febrile Neutrophilic Dermatosis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Acute Febrile Neutrophilic Dermatosis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It…
Febrile Neutropenia Market Growth Prospects, Trends and Forecast up to 2030
Regular Patient Monitoring Reduces Stress on Clinicians amidst COVID-19 Outbreak
Patients with febrile neutropenia are at a high risk of contracting the coronavirus (COVID-19) infection. Hence, pharma companies in the febrile neutropenia market are increasing their production capabilities to manufacture intravenous (IV) antibiotics to avoid supply shocks in healthcare settings. Manufacturers are educating clinicians to conduct regular computed tomography (CT) scan of the chest of febrile neutropenia patients even in the…
